Recombinant neorudin and its active metabolite hirudin: the fate of a novel anticoagulant drug
Pharmacokinetic review published in Frontiers in Pharmacology (2024)
Abstract
Thrombosis, a prevalent condition, can provoke severe health issues like acute coronary syndrome (ACS), deep vein thrombosis (DVT), and pulmonary embolism (PE). The rising incidence of these diseases annually significantly impacts patient wellbeing and poses a substantial burden on healthcare systems. Recombinant neorudin is a developing anticoagulant drug for thrombotic diseases whose phase I clinical trials has been completed. The distribution pattern of it and its active metabolite, hirudin, in thrombi, blood surrounding the thrombus and peripheral blood remains uncertain. This study explored their distribution using a rat arteriovenous bypass thrombosis model, revealing higher neorudin levels in blood surrounding the thrombus and elevated hirudin concentrations in thrombus. Recombinant neorudin significantly increased Thrombin Time (TT) in both plasma surrounding the thrombus and peripheral blood, and reduced the wet weight of the thrombus. The results above demonstrated the anticoagulant and antithrombotic efficacy of recombinant neorudin in vivo. Give the distribution pattern of neorudin and hirudin, we hypothesized that neorudin was cleaved at the site of thrombus formation to produce hirudin, leading to the rapid accumulation of hirudin within local thrombi and resulting in a higher concentration inside the thrombus. This insight was crucial for understanding the action mechanisms of anticoagulants in thrombosis management and provided a valuable guidance for therapeutic strategies in treating thrombotic diseases.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Reviews preclinical and clinical pharmacology of neorudin, a thrombin-activated recombinant prodrug of hirudin variant 2 — covers ADME, metabolism, efficacy, and bleeding-risk advantages.
Why This Matters for Hirudotherapy
This study examined the distribution of recombinant neorudin—described in the abstract as a developing anticoagulant drug whose active metabolite is hirudin—and of hirudin itself, using a rat arteriovenous bypass thrombosis model. Neorudin levels were higher in blood surrounding the thrombus while hirudin concentrations were elevated within the thrombus; neorudin significantly prolonged thrombin time in both plasma surrounding the thrombus and peripheral blood, and reduced thrombus wet weight. The authors hypothesized that neorudin is cleaved at the thrombus site to release hirudin, leading to local accumulation, and stated this insight provides valuable guidance for therapeutic strategies in treating thrombotic diseases. For ASH, this is relevant because the active metabolite studied is hirudin, a compound central to ASH's domain, though the key caveat is that all findings are from a rat model, the cleavage mechanism is hypothesized rather than directly demonstrated, and no human data are presented.
Citation
Recombinant neorudin and its active metabolite hirudin: the fate of a novel anticoagulant drug.
Li Q et al. · Frontiers in pharmacology, 2024
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026